Last reviewed · How we verify
NCT07479667: dendritic cell
An Antibody-armored Dendritic Cell in Patients With Solid Tumors
Phase 1 trial testing Armored Dendritic Cell Injection in Solid Cancers in 8 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Shanghai Cell Therapy Group Co.,Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 5 February 2026 |
| Primary completion | 31 December 2028 |
| Estimated completion | 30 June 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Armored Dendritic Cell Injection — full drug profile →
Conditions studied
- Solid Cancers — all drugs for Solid Cancers →
- Adjuvant Therapy — all drugs for Adjuvant Therapy →
Sponsor
Shanghai Cell Therapy Group Co.,Ltd — full company profile →
Who can join
Adults 18 to 80, any sex, with Solid Cancers or Adjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, open-label, single-administration dose-escalation study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07479667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Cancers
Currently open trials in the same condition.
- NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
- NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
- NCT07058948 — Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors · Phase 2 · recruiting
- NCT06883539 — A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. · Phase 1 · recruiting
Other Shanghai Cell Therapy Group Co.,Ltd trials
Trials by the same sponsor.
- NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting
- NCT07414381 — An Exploratory Study of Chenghuang Circadian Rhythm Regulator in Subjects With Sleep Disorders · NA · completed
- NCT06732232 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06446128 — A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL) · EARLY_PHASE1 · recruiting
- NCT06327997 — An Exploratory Study by Fast CAR T Cells · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07479667 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Cell Therapy Group Co.,Ltd
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07479667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing